Dacheng Hang Seng Health Care ETF(QDII)(159303.SZ)

Company Encyclopedia
View More
name
Dacheng Hang Seng Health Care ETF(QDII)
159303.SZ
News
View More

21:29 ET Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China

Akeso, Inc. announced that its bispecific antibody AK152, targeting amyloid-beta (Aβ) and blood-brain barrier (BBB) expressed receptor, has been approved for clinical trials for Alzheimer's Disease in China. AK152 is the first bispecific antibody developed in China for Alzheimer's, marking a significant breakthrough. It enhances brain penetration and accelerates Aβ plaque clearance, showing promising preclinical results. This approval expands Akeso's R&D pipeline into neurodegenerative diseases.

prnewswire·
HK
09926
-0.47%
prnewswire·
HK
09926
-0.47%

Akeso Inc. Wins China Approval for Ivonescimab in EGFR-Mutated NSCLC

Akeso Inc. has received regulatory approval from the China National Medical Products Administration for its therapy ivonescimab, aimed at treating EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) after EGFR-TKI progression. The drug will be included in China's National Reimbursement Drug List starting January 1, 2025, ensuring patient access. Additionally, Summit Therapeutics plans to submit a Biologics License Application to the U.S. FDA in Q4 2025 for the same indication.

Reuters·
HK
09926
-0.47%
Reuters·
HK
09926
-0.47%

CSPC PHARMA: SYH2070 injection (double-stranded small interfering RNA drug) has received clinical trial approval in the United States

CSPC PHARMA announced that its self-developed SYH2070 injection has been approved by the U.S. FDA for clinical trials. This drug is a double-stranded small interfering RNA designed to lower ANGPTL3 levels by targeting angiopoietin-like protein 3, suitable for hypertriglyceridemia or mixed hyperlipidemia. Preclinical studies have shown that it outperforms similar products in terms of drug activity and persistence, demonstrating high clinical development value

Zhitong·
HK
01093
+0.99%
Zhitong·
HK
01093
+0.99%

CSPC PHARMA: Tacrolimus sustained-release capsules have received drug registration approval

CSPC PHARMA announced that its developed tacrolimus sustained-release capsules (0.5mg, 1mg) have obtained the drug registration approval from the National Medical Products Administration of China and have passed the consistency evaluation of quality and efficacy for generic drugs. This medication is an immunosuppressant suitable for the prevention and treatment of rejection reactions after kidney and liver transplantation, and its approval will enrich the group's product line in the field of immune rejection treatment

Zhitong·
HK
01093
+0.99%
Zhitong·
HK
01093
+0.99%

Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial

Akeso Inc. announced a significant label update for its bispecific antibody, ivonescimab, after approval by China's National Medical Products Administration. The update is based on the HARMONi-A Phase III trial, showing significant improvements in progression-free survival (PFS) and overall survival (OS) for patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC) post-EGFR-TKI therapy. The final analysis indicated a 26% reduction in death risk and a 54% reduction in disease progression risk compared to chemotherapy alone. Ivonescimab is now included in China's National Reimbursement Drug List for specific NSCLC indications.

Reuters·
HK
09926
-0.47%
Reuters·
HK
09926
-0.47%
© 2026 Longbridge｜Disclaimer